Document Detail


Consistency in the safety labeling of bioequivalent medications.
MedLine Citation:
PMID:  23042584     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: Bioequivalent medications are required by the Food and Drug Administration to have identical warnings on their labels. This requirement has both clinical and legal importance, yet has never been validated. We sought to determine the real-world consistency of electronic labeling for bioequivalent drugs from different manufacturers. METHODS: Using natural language processing, we indexed the adverse drug reactions (ADRs) found in the Adverse Reactions and Post-Marketing sections of 9105 structured product labels. We calculated the standard deviation in ADR labeling for each bioequivalent drug and the percent deviation of each generic label from its corresponding brand. We also analyzed the performance of individual generic manufacturers. For the 25 drugs with the greatest discrepancy in labeled ADRs, we performed manual review to identify causes of inconsistency. RESULTS: 68% of multi-manufacturer drugs had discrepancies in ADR labeling. For a given drug, the mean deviation in number of labeled ADRs was 4.4, and the median was 0.8 (IQR 0 to 3.2). The mean range in number of labeled ADRs was 12 +/- 0.9, and the median was 2 (IQR 0 to 9). Overall, 77.9% of generic manufacturers produced labels differing from brand. Causes of inconsistency included missing tables, outdated post-marketing reports, and formatting issues. CONCLUSIONS: Despite FDA mandate, bioequivalent drugs often differ in their safety labeling. Physicians should be aware of such differences and regulators should consider new strategies for harmonizing bioequivalent labels. Copyright © 2012 John Wiley & Sons, Ltd.
Authors:
Jon Duke; Jeff Friedlin; Xiaochun Li
Related Documents :
477644 - Effectiveness of clonazepan in startle-induced seizures.
25079434 - Physicochemical characterization of asulacrine towards the development of an anticancer...
23000494 - Eight flavonoids and their potential as inhibitors of human cytomegalovirus replication.
23443074 - Finding the targets of a drug by integration of gene expression data with a protein int...
18006844 - Chemosensitization of b-cell lymphomas by methylseleninic acid involves nuclear factor-...
365634 - I-bar: myth and countermyth.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-8
Journal Detail:
Title:  Pharmacoepidemiology and drug safety     Volume:  -     ISSN:  1099-1557     ISO Abbreviation:  Pharmacoepidemiol Drug Saf     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9208369     Medline TA:  Pharmacoepidemiol Drug Saf     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 John Wiley & Sons, Ltd.
Affiliation:
Regenstrief Institute, Indianapolis, IN, USA; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. jduke@regenstrief.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Attenuation of KBrO(3) -Induced Renal and Hepatic Toxicity By Cloudy Apple Juice In Rat.
Next Document:  Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome.